Drugs / TTHX1114
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05769920 | Dec 2022 → Apr 2023 | corneal degeneration | Trefoil Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04520321 | Aug 2020 → Apr 2021 | Fuchs' endothelial dystrophy, bullous keratopathy | Trefoil Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04812067 | Nov 2021 → Aug 2023 | corneal endothelial dystrophy | Trefoil Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04676737 | Feb 2021 → Nov 2022 | Fuchs atrophia gyrata chorioideae et retinae, Fuchs' endothelial dystrophy | Trefoil Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-05-10 | Trefoil Therapeutics, Inc. | Results Trefoil Therapeutics’ Lead Investigational Candidate TTHX1114 Improves Rate of Visual Recovery after Descemet Stripping Only (DSO) in Phase 2 STORM Data Presented at ASCRS Annual Meeting trefoiltherapeutics.com ↗
The study results showed TTHX1114 improved best-corrected visual acuity (BCVA) and central corneal thickness (CCT) after DSO in the 49 subjects/64 eyes. |
| 2023-04-25 | Trefoil Therapeutics, Inc. | Results New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgery trefoiltherapeutics.com ↗
New findings included: Across all patients, TTHX1114 produced a dose-dependent response in resolution of corneal edema and improvement of best corrected visual acuity (BCVA) following surgery. |
| 2022-09-29 | Trefoil Therapeutics, Inc. | Results Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery following Descemet Stripping Only (DSO) Surgery trefoiltherapeutics.com ↗
Trefoil Therapeutics, a clinical-stage biotechnology company focused on restoring sight to people with corneal diseases, today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy (FECD). |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TTHX1114 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05769920 ↗ |
| Known as | NM141 | “TTHX1114(NM141) Ophthalmic Solution” NCT05769920 ↗ |
| Modality | Protein / enzyme biologic | “engineered FGF-1” NCT04520321 ↗ |
| Route | Other | “delivered intracamerally” NCT04520321 ↗ |